Drugs targeting the renin-angiotensin-aldosterone system

Related Experiment Video

Updated: Sep 28, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Mohammad Amin Zaman1, Suzanne Oparil, David A Calhoun

  • 1Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA. amin.zaman@ccc.uab.edu

Nature Reviews. Drug Discovery
|October 31, 2002
PubMed

Insights

Antihypertensive therapies reduce cardiovascular disease, but risks remain high. New drugs targeting the renin-angiotensin-aldosterone system offer improved protection by addressing blood pressure and organ damage.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension Research

Background:

  • Effective antihypertensive therapy has significantly reduced cardiovascular disease (CVD) morbidity and mortality since the 1960s.
  • Conventional blood-pressure-lowering drugs have not fully eliminated CVD risks, leaving residual risk in treated individuals.
  • Normotensive individuals exhibit lower cardiovascular disease risks, highlighting the importance of optimal blood pressure control.

Purpose of the Study:

  • To evaluate the role of drugs inhibiting or antagonizing the renin-angiotensin-aldosterone system (RAAS).
  • To assess the potential of RAAS-targeting drugs in further reducing cardiovascular disease risks.
  • To investigate the mechanisms by which these drugs prevent target-organ damage and cardiovascular events.

Main Methods:

  • Review of clinical trials and epidemiological studies on antihypertensive therapies.
  • Analysis of pharmacological data on drugs affecting the renin-angiotensin-aldosterone system.
  • Examination of evidence for the impact of these drugs on cardiac and vascular structure and function.

Main Results:

  • RAAS-inhibiting drugs demonstrate efficacy in both lowering blood pressure and mitigating structural/functional abnormalities.
  • These agents show promise in preventing target-organ damage, including cardiac hypertrophy and vascular remodeling.
  • Evidence suggests a superior cardiovascular risk reduction profile compared to some conventional therapies.

Conclusions:

  • Drugs targeting the renin-angiotensin-aldosterone system represent a significant advancement in managing hypertension and its cardiovascular sequelae.
  • By addressing both blood pressure and organ-specific damage, these therapies offer enhanced protection against cardiovascular events.
  • Further research and clinical application of RAAS-targeting drugs are crucial for optimizing cardiovascular disease prevention.

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...